Skip to main content
WST
NYSE Industrial Applications And Services

West Pharma Reports Strong Q1, Raises Full-Year Guidance, and Executes Significant Share Repurchase

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Medical Instrument Stocks · Healthcare
Sentiment info
Positive
Importance info
8
Price
$325.01
Mkt Cap
$19.78B
52W Low
$199.89
52W High
$322.34
52W Position info
63% above low
Off High info
at 52W high
Rel. Volume info
1.0× avg
Market data snapshot near publication time

WST sits 63% above its 52-week low of $199.89.

Summary

West Pharmaceutical Services reported strong first-quarter results, raised its full-year 2026 financial guidance, and repurchased $297.6 million in shares, signaling robust performance and management confidence.


Key Events · Earnings and Guidance · WST

  • Strong First Quarter 2026 Results

    The company reported net sales of $844.9 million, a 21.0% increase (15.3% organic), and diluted EPS of $1.92, up 56.1% year-over-year. Adjusted-diluted EPS rose 46.9% to $2.13.

  • Full-Year 2026 Guidance Raised

    West Pharmaceutical Services increased its full-year 2026 net sales guidance to a range of $3.295 billion to $3.350 billion (up from $3.215 billion to $3.275 billion) and adjusted-diluted EPS guidance to $8.40 to $8.75 (up from $7.85 to $8.20).

  • Significant Share Repurchase

    The company repurchased 1.2 million shares for $297.6 million during Q1 2026, at an average price of $243.57 per share, under its previously announced program.

  • GLP-1 Market Driving Growth

    GLP-1 related revenues contributed significantly, with elastomer revenues accounting for 10% and West Vantage revenues for 8% of total company sales in Q1 2026.


Analysis · WST · Industrial Applications And Services

West Pharmaceutical Services delivered a robust first quarter, significantly exceeding expectations with strong revenue and EPS growth. The company's decision to raise its full-year 2026 guidance for both net sales and adjusted EPS signals strong confidence in continued momentum, driven by high-value products and the GLP-1 market. Furthermore, the execution of a substantial share repurchase program, amounting to nearly $300 million, demonstrates a commitment to returning capital to shareholders and reflects management's positive outlook, especially as the stock trades near its 52-week high. This filing formalizes the positive news that was concurrently reported by news outlets.

At the time of this filing, WST was trading at $325.01 on NYSE in the Industrial Applications And Services sector, with a market capitalization of approximately $19.8B. The 52-week trading range was $199.89 to $322.34. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

WST - Latest Insights

WST
Jul 23, 2026, 4:15 PM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $354.08
Real-time Price: $328.20 info
Change: -$25.88 (-7%) info
Market Cap: $23.097B info
WST
Jul 23, 2026, 7:14 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $380.00
Real-time Price: $328.20 info
Change: -$51.80 (-14%) info
Market Cap: $23.097B info
WST
Jul 23, 2026, 6:34 AM EDT
Source: dpa-AFX
Importance Score:
8
Price at Filing: $360.20
Real-time Price: $328.20 info
Change: -$32.00 (-9%) info
Market Cap: $23.097B info
WST
Jul 23, 2026, 6:00 AM EDT
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $360.20
Real-time Price: $328.20 info
Change: -$32.00 (-9%) info
Market Cap: $23.097B info
WST
Jun 01, 2026, 4:32 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $316.75
Real-time Price: $328.20 info
Change: +$11.45 (+4%) info
Market Cap: $23.097B info